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A B S T R A C T
Background
Dyspnoea is a common symptom in advanced cancer, with a prevalence of up to 70% among patients at end of life. The cause of dyspnoea is
oMen multifactorial, and may cause considerable psychological distress and suHering. Dyspnoea is oMen undertreated and good symptom
control is less frequently achieved in people with dyspnoea than in people with other symptoms of advanced cancer, such as pain and
nausea. The exact mechanism of action of corticosteroids in managing dyspnoea is unclear, yet corticosteroids are commonly used in
palliative care for a variety of non-specific indications, including pain, nausea, anorexia, fatigue and low mood, despite being associated
with a wide range of adverse eHects. In view of their widespread use, it is important to seek evidence of the eHects of corticosteroids for
the management of cancer-related dyspnoea.
Objectives
To assess the eHects of systemic corticosteroids for the management of cancer-related breathlessness (dyspnoea) in adults.
Search methods
We searched CENTRAL, MEDLINE, Embase, CINAHL, Science Citation Index Web of Science, Latin America and Caribbean Health Sciences
(LILACS) and clinical trial registries, from inception to 25 January 2018.
Selection criteria
We included randomised controlled trials that included adults aged 18 years and above. We included participants with cancer-related
dyspnoea when randomised to systemic corticosteroids (at any dose) administered for the relief of cancer-related dyspnoea or any other
indication, compared to placebo, standard or alternative treatment.
Data collection and analysis
Five review authors independently assessed trial quality and three extracted data. We used means and standard deviations for each
outcome to report the mean diHerence (MD) with 95% confidence interval (CI). We assessed the risk of bias and quality of evidence using
GRADE. We extracted primary outcomes of sensory-perceptual experience of dyspnoea (intensity of dyspnoea), aHective distress (quality
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of dyspnoea) and symptom impact (burden of dyspnoea or impact on function) and secondary outcomes of serious adverse events,
participant satisfaction with treatment and participant withdrawal from trial.
Main results
Two studies met the inclusion criteria, enrolling 157 participants (37 participants in one study and 120 in the other study), of whom 114
were included in the analyses. The studies compared oral dexamethasone to placebo, followed by an open-label phase in one study. One
study lasted seven days, and the duration of the other study was 15 days.
We were unable to conduct many of our predetermined analyses due to diHerent agents, dosages, comparators and outcome measures,
routes of drug delivery, measurement scales and time points. Subgroup analysis according to type of cancer was not possible.
Primary outcomes
We included two studies (114 participants) with data at one week in the meta-analysis for change in dyspnoea intensity/dyspnoea relief
from baseline. Corticosteroid therapy with dexamethasone resulted in an MD of lower dyspnoea intensity compared to placebo at one week
(MD –0.85 lower dyspnoea (scale 0–10; lower score = less breathlessness), 95% CI -1.73 to 0.03; very low-quality evidence), although we
were uncertain as to whether corticosteroids had an important eHect on dyspnoea as results were imprecise. We downgraded the quality
of evidence by three levels from high to very low due to very serious study limitations and imprecision.
One study measured aHective distress (quality of dyspnoea) and results were similar between groups (29 participants; very low-quality
evidence). We downgraded the quality of the evidence three times for imprecision, inconsistency, and serious study limitations.
Both studies assessed symptom impact (burden of dyspnoea or impact on function) (113 participants; very low-quality evidence). In one
study, it was unclear whether dexamethasone had an eHect on dyspnoea as results were imprecise. The second study showed more
improvement for physical well-being scores at days eight and 15 in the dexamethasone group compared with the control group, but there
was no evidence of a diHerence for FACIT social/family, emotional or functional scales. We downgraded the quality of the evidence three
times for imprecision, inconsistency, and serious study limitations.
Secondary outcomes
Due to the lack of homogenous outcome measures and inconsistency in reporting, we could not perform quantitative analysis for any
secondary outcomes. In both studies, the frequency of adverse events was similar between groups, and corticosteroids were generally well
tolerated. The withdrawal rates for the two studies were 15% and 36%. Reasons for withdrawal included lost to follow-up, participant or
carer (or both) refusal, and death due to disease progression. We downgraded the quality of evidence for these secondary outcomes by
three levels from high to very low due to serious study limitations, inconsistency and imprecision.
Neither study examined participant satisfaction with treatment.
Authors' conclusions
There are few studies assessing the eHects of systemic corticosteroids on cancer-related dyspnoea in adults with cancer. We judged the
evidence to be of very low quality that neither supported nor refuted corticosteroid use in this population. Further high-quality studies are
needed to determine if corticosteroids are eHicacious in this setting.
P L A I N   L A N G U A G E   S U M M A R Y
Corticosteroids for the management of cancer-related breathlessness in adults with cancer
Background
Breathlessness (dyspnoea) is a common symptom in advanced cancer. Breathlessness may be due to a combination of diHerent causes
including lung cancer, metastatic disease elsewhere in the body (for example, cancer in the abdomen pushing up the diaphragm), or cancer-
related conditions aHecting the nerves or muscles associated with breathing. Pain and psychological conditions (such as fear and anxiety)
or pre-existing lung disease may make symptoms worse. People with cancer report breathlessness is associated with higher psychological
distress and poorer quality of life. Medicines can be used to treat breathlessness in this population, and one common medicine used is
corticosteroids. In this review, we evaluated how eHective systemic corticosteroids are in treating cancer-related breathlessness in adults,
compared to any control.
Study characteristics
We searched the literature in January 2018. We found two studies, enrolling 157 participants in total, that tested the eHect of systemic
corticosteroids on breathlessness in adults with cancer, compared to a dummy medicine (placebo). One study lasted seven days, and
the other study lasted 15 days. Both studies compared a corticosteroid (oral (by mouth) dexamethasone) to a dummy medicine with no
properties to reduce breathlessness, which we included in our analyses.
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We were interested in the primary outcomes of participant-reported breathlessness intensity, quality and burden. We were also interested
in the secondary outcomes of serious side eHects, participant satisfaction with treatment and participant withdrawal from trial.
Key results
We could not complete many of our planned analyses due to the small number of studies, the diHerent medicines and comparisons, and
outcomes that the studies reported. We did conduct one analysis of 114 participants to assess change in breathlessness intensity/relief
from baseline. We found that corticosteroids had no beneficial eHect compared to a dummy medicine on reducing breathlessness intensity
in people with cancer.
We found that the frequency of side eHects was similar between groups, and corticosteroids were generally well tolerated. None of the
studies measured participant satisfaction with treatment. Participant withdrawals were 15% and 36% in the two studies.
Quality of evidence
The current evidence was based on only two studies with a small number of participants. We rated the quality of the evidence from these
studies using four levels: very low, low, moderate or high. Very low-quality evidence means that we are very uncertain about the results.
High-quality evidence means that we are very confident in the results. We judged the quality of the evidence in this review to be very
low, downgraded due to problems with study quality and too few data. We are very uncertain of the results. More high-quality studies are
needed to determine if corticosteroids are eHective for dyspnoea in people with cancer.
Systemic corticosteroids for the management of cancer-related breathlessness (dyspnoea) in adults (Review)






























































































S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.   Systemic corticosteroids compared with placebo for the management of cancer-related
breathlessness (dyspnoea)
Systemic corticosteroids compared with placebo for the management of cancer-related breathlessness (dyspnoea)
Patient or population: adults with cancer-related breathlessness (dyspnoea)
Settings: inpatients and outpatients
Intervention: dexamethasone
Comparison: placebo
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Adverse events Severity of adverse events was not properly defined making it difficult
to assess this outcome. The frequency of adverse events was similar









No data No data No data No data No data Not possible
to GRADE this
outcome due




54 withdrawals out of 173 participants (31%) for the two studies.








GRADE Working Group grades of evidence
High quality: we are very confident that the true effect lies close to that of the estimate of the effect;
Moderate quality: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substan-
tially different;
Low quality: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect;
Very low quality: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.
aDowngraded the quality of the evidence once for imprecision due to the small number of participants in the included studies, and twice for very serious study limitations (likely
selection and attrition bias).
bDowngraded the quality of the evidence three times: once for imprecision due to the small number of participants in the included study, once for inconsistency, and once for
serious study limitations (likely attrition bias).
cDowngraded the quality of the evidence three times: once for imprecision due to the small number of participants in the included studies, once for inconsistency, and once for
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B A C K G R O U N D
Description of the condition
Dyspnoea (breathlessness) is a "subjective experience of breathing
discomfort that consists of qualitatively distinct sensations that
vary in intensity" (American Thoracic Society 1999). It is "one of
the most common and most feared symptoms amongst cancer
patients" (Hui 2013), increases with disease progression (Solano
2006), and occurs in up to 70% of people with advanced cancer
at end of life (Bruera 2000; Dudgeon 2001; Hui 2015; Kutner
2001; Mercadante 2017; Tishelman 2007; Viola 2008). Dyspnoea
has a negative impact on a patient's quality of life. It interferes
with daily life activities (ERS Monograph 2016; Mercadante 2017;
Tanaka 2002a), and has been associated with fatigue, anxiety and
depression, and decreased function and quality of life, since it may
precipitate both physical and psychological distress (Ben-Aharon
2012; ERS Monograph 2016; Mularski 2010; Seow 2011; Tanaka
2002b; Williams 2006). It may cause significant suHering for patients
and their families (Bernhard 1991; Booth 2008), and be a source of
substantial healthcare expenditure (Booth 2003; Booth 2015; ERS
Monograph 2016; Johnson 2014; Seamark 2004; Skaug 2009). It
is frightening for many patients who report feeling that they are
suHocating, choking (Skevington 1997), short of breath, unable to
get a breath or drowning (eTG 2016; Kloke 2015; Parshall 2012;
Wilcock 2002).
Good symptom control is less frequently achieved in people
with dyspnoea than in people with other symptoms of advanced
cancer, such as pain and nausea (Yennurajalingam 2015). When
disease is advanced, patients may experience episodes of
acute breathlessness (Mercadante 2017), "superimposed on a
background level of continuous breathlessness" (Johnson 2016).
Episodes of breathlessness may be predictable (generally caused
by physical exertion) or unpredictable (Johnson 2016; Simon 1990).
The pathophysiology of dyspnoea is complex and is not fully
understood (Booth 2008; Burki 2010; ERS Monograph 2016; Hui
2013; Manning 1995; Parshall 2012). A constellation of sensory
inputs may contribute to the multiple sensations of dyspnoea,
which may include the "sensations of work or eHort, tightness,
and air hunger/unsatisfied inspiration" (Parshall 2012). Tightness is
relatively specific to stimulation of airway receptors in conjunction
with bronchoconstriction, while intensity of air hunger/unsatisfied
inspiration is magnified by imbalances among inspiratory drive,
eHerent activation (outgoing motor command from the brain),
and feedback from aHerent receptors throughout the respiratory
system (Parshall 2012). In the palliative care setting, the cause
of dyspnoea is oMen multifactorial (ERS Monograph 2016), with
an unpredictable response to treatment (Lin 2012). Indeed, the
subjective experience of dyspnoea is influenced by "multiple
physical, psychological, social and spiritual factors, and may induce
secondary physiological and behavioral responses" (Lok 2016).
The concept of 'total dyspnoea' – similar to that of 'total pain' –
may provide a framework in the multidimensional assessment and
management of breathlessness (Abernethy 2008; ERS Monograph
2016), as each of these factors may contribute to the perceived
severity of a person's dyspnoea (Banzett 2008; Chin 2016; De Peuter
2004; Evans 2002; Parshall 2012).
Common pulmonary causes of dyspnoea in cancer may include
progressive metastatic disease, lymphangitis carcinomatosa,
pleuritis carcinomatosa, pleural eHusion, interstitial lung disease,
parenchymal lung involvement, pulmonary embolism, infection,
atelectasis, airway obstruction and pre-existing pulmonary disease
(Booth 2014; Chan 2004; eTG 2016; Kvale 2007; Manning
1995). Systemic causes of dyspnoea may include anaemia,
hypoxaemia, uraemia or acidaemia, congestive cardiac failure,
pericarditis or pericardial eHusion, pulmonary hypertension,
sepsis, cardiovascular/physical deconditioning, muscle weakness
or neuromuscular conditions (Booth 2014; Parshall 2012). Other
common causes include pain, ascites, hepatomegaly, obesity,
lymphadenopathy, superior vena cava obstruction, treatment-
related adverse eHects (e.g. pneumonitis or fibrosis following
chemotherapy or radiotherapy) and pre-existing lung disease
(e.g. asthma or chronic obstructive pulmonary disease (COPD)).
Psychological drivers or psychogenic causes, such as panic
disorder, anxiety and distress, may also contribute to the genesis
of breathlessness or further compound symptoms, or both
(Giardino 2010; Kunik 2005; Moore 1999; Nardi 2009; Parshall
2012; Perna 2004; Rassovsky 2006; Smoller 1996; Williams 2010).
The symptoms of dyspnoea are usually managed following
careful assessment of the potential cause and impact on the
person's experience, and treatment of any reversible causes
(Chin 2016; Manning 1995). Dyspnoea that appears suddenly
is more likely to be reversible than progressive longstanding
dyspnoea that is related to disease progression as it is likely
to be related to a treatable acute event such as infection or
pulmonary embolism (eTG 2016). Therefore, it is important to
consider assessment for potentially reversible causes of dyspnoea
(eTG 2016). As the sensation of dyspnoea is mediated by the
central nervous system (Herigstad 2011), strategies that address
psychosocial stressors or psychological triggers are also key, to
"reduce the impact of the sensation of breathlessness, even
when it cannot be removed" (Booth 2015). Therefore, non-
pharmacological techniques are of central importance in the
management of breathlessness (Booth 2015; Farquhar 2014),
and active management of psychosocial issues such as anxiety,
depression, carer stress and distress, and the implementation of
non-pharmacological self-management strategies such as physical
and mental activity, relaxation techniques, breathing exercises,
education and information should be a priority (Booth 2015).
Modification of the patient's environment, activity pacing and
energy conservation (Sackley 2009), and anxiety reduction training
(Lai 2010), may also maximise comfort, improve respiratory
eHiciency, and reduce fear and anxiety (De Peuter 2004;
eTG 2016; Farquhar 2014; Higginson 2014; Kamal 2012). For
example, the use of a fan is one of the most important and
eHective non-pharmacological interventions in the management
and relief of breathlessness (Bausewein 2008; Galbraith 2010).
Johnson and colleagues postulated that "as skeletal muscle
(not limited to the muscles of respiration) is intimately involved
in the genesis of breathlessness, reduced activity leads to
reduced muscle bulk so that over time, breathlessness will be
triggered by less and less exertion breathlessness" (Johnson
2014). Exercise-based rehabilitation, a complex intervention that
incorporates cognitive and behavioural management strategies
(Parshall 2012), pulmonary rehabilitation, and other integrated,
complex intervention services for breathlessness may thus be
of use or benefit for people with dyspnoea (Booth 2006; Booth
2011; Farquhar 2010; Farquhar 2014). From an anxiety reduction
training point of view, cognitive behavioural therapy, simple
relaxation therapy, distraction methods, music or mindfulness
may also help people feel more control (Lok 2016), and 'gain
mastery' over their breathlessness (Booth 2014). For severe,
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chronic, refractory or intractable dyspnoea, non-pharmacological
methods may be supplemented by pharmacological treatments.
These may include oral or parenteral opioids (Ben-Aharon 2012;
Johnson 2014; Parshall 2012; Viola 2008), benzodiazepines (if
the person is experiencing significant anxiety), alongside other
non-pharmacological strategies (ERS Monograph 2016), oxygen
(if a person is hypoxic) (Parshall 2012), and steroids (eTG 2016;
Kamal 2012). Systemic corticosteroids are also commonly used
for specific antitumour eHect in conditions such as lymphangitis
carcinomatosa or airway obstruction by tumour (Elsayem 2007).
Description of the intervention
Systemic corticosteroids are commonly used in palliative care
practice for symptom control of fatigue (Yennurajalingam 2013),
nausea and vomiting (Vayne-Bossert 2017), anorexia, cachexia and
pain, relief of spinal cord compression, reduction of vasogenic
oedema from brain metastasis and resolution from malignant
bowel obstruction (Hardy 2001; Lin 2012; Mercadante 2001;
Paulsen 2014; Shih 2007). The corticosteroid used most commonly
in palliative care is dexamethasone, due to its potency, long
duration of action allowing once-daily dosing and the ability to
administer it subcutaneously (eTG 2016). The balance of benefit
versus risk of harm must be carefully considered. Adverse eHects
are usually dose and duration related, and include insomnia,
mental disturbances (including depression, mania, psychosis or
delirium), hyperglycaemia, increased susceptibility to infection,
gastric irritation, Cushingoid features and proximal myopathy (eTG
2016).
How the intervention might work
Dyspnoea, or the sensation of breathlessness, is closely related to
the sensation of respiratory eHort experienced via the activation of
proprioceptive pathways during respiration (Dorman 2009). While
the respiratory centre in the medulla controls breathing, dyspnoea
is the result of cortical stimulation (Dorman 2009; Hui 2013).
Both lung and central chemoreceptors detect abnormalities in
blood gases (hypoxia, increased partial pressure of carbon dioxide),
and together with lung and respiratory muscle mechanoreceptors
(responding to stretching and pulmonary irritants), stimulate the
medullary respiratory centre. The activity of the chemoreceptors,
mechanoreceptors and respiratory centre can also stimulate
the cerebral cortex, thus directly contributing to the sensation
of dyspnoea (Dorman 2009; Hui 2013). Cancer, in a similar
manner to COPD, is characterised by a significant inflammatory
component that includes airway wall infiltration of macrophages
and T lymphocytes, increased lung tumour necrosis factor-
alpha and interleukin (IL)-8, elevated serum IL-6, C-reactive
protein, increased peripheral neutrophil activation (Hui 2016),
and inflammatory cytokines (Wang 2010). Corticosteroids have
potent anti-inflammatory activity that may explain their ability to
alleviate dyspnoea, as people with advanced cancer oMen have an
elevated inflammatory response that can contribute to dyspnoea
both peripherally and centrally (Hui 2016). The usefulness of the
anti-inflammatory activity of corticosteroids in managing acute
exacerbations of COPD is well established (Barczyk 2004; Brightling
2000; Culpitt 2003; Falk 2008; Wood-Baker 2005). However, as
dyspnoea is likely to be multifactorial in the context of cancer,
corticosteroids may work more eHectively in some instances (e.g.
where there is a process of inflammation), but not as well in other
instances.
Why it is important to do this review
Dyspnoea is a common and devastating symptom in people
with cancer that oMen worsens in the last months of life and
may be diHicult to treat (Dudgeon 2001; Hui 2015; Hui 2016;
Mercadante 2017; Tishelman 2007). Systemic corticosteroids are
commonly used in palliative care, particularly for people with
advanced malignant disease, for a variety of symptom control
indications including pain, nausea, vomiting, anorexia, fatigue
and dyspnoea (Lin 2012; Shih 2007), despite the fact that
steroids may be associated with significant adverse eHects (Matsuo
2011), especially following long-term use. However, there is little
objective evidence in the literature to support the use of systemic
corticosteroids for symptom control (ERS Monograph 2016; Viola
2008), and concerns have been raised about the 'uncontrolled' use
of steroids in people with cancer (Haywood 2015; Levy 2016; Vayne-
Bossert 2017).
O B J E C T I V E S
To assess the eHects of systemic corticosteroids for the
management of cancer-related breathlessness (dyspnoea) in
adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised double-blind controlled trials (RCTs) with
full journal publication, as well as online clinical trial results and
summaries of otherwise unpublished clinical trials or abstracts
with suHicient data for analysis. We excluded studies that were
non-randomised, case reports and clinical observations, and short
abstracts (usually meeting reports).
Types of participants
Participants with cancer with cancer-related dyspnoea, aged 18
years and above.
Types of interventions
Systemic corticosteroids at any dose, administered for the relief
of cancer-related dyspnoea or other cancer-related symptoms
(where dyspnoea was also measured), compared to placebo or
any active comparator including supportive care or alternate non-
pharmacological treatment. We excluded studies assessing inhaled
corticosteroids.
Types of outcome measures
Primary outcomes
• Our primary outcome was the eHect of systemic corticosteroids
on breathlessness (dyspnoea), as assessed by the American
Thoracic Society 'Domains of Dyspnoea Measurement' (Parshall
2012).
Domain 1: Sensory-perceptual experience – intensity of dyspnoea
Definition: measures of what breathing feels like to the patient or
research subject. Examples include:
• single-item ratings of intensity such as the Borg scale (Borg
1982), Visual Analogue Scale (VAS) (GiM 1989).
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Domain 2: A<ective distress – quality of dyspnoea
Definition: measures of how distressing breathing feels. Focus
can be either immediate (e.g. unpleasantness) or evaluative (e.g.
judgements of meaning or consequence). Examples include:
• single-item ratings of severity of distress or unpleasantness; and
• multi-item scales of emotional responses such as anxiety such
as the Hospital Anxiety and Depression Scale (HADS), or State-
Trait Anxiety Inventory (STAI).
Domain 3: Symptom impact-burden of dyspnoea/impact on function
Definition: measures of how dyspnoea aHects functional ability,
employment (disability), quality of life or health status. Examples
include:
• unidimensional rating of disability or activity limitation such
as the Medical Research Council (MRC) Dyspnoea Scale (Mahler
1988);
• unidimensional or multidimensional ratings of functional ability
(Pulmonary Functional Status and Dyspnoea Questionnaire
(PFSDQ) (Lareau 1998); and
• multidimensional scales of quality of life/health status.
We aimed to use both standardised, mean pre–post change
in breathlessness scores aMer the intervention (comparator), as
well as post-intervention standardised mean diHerence (SMD)
in breathlessness scores between intervention and comparator
groups. We aimed to also summarise breathlessness outcomes
separately, to delineate between breathlessness measured 'now'
versus 'on average over the past 24 hours' or as described by the
validated outcome measure.
We aimed to obtain standardised means when seeking to
summarise and compare studies that use diHerent breathlessness
measures (regardless of the scoring system).
Secondary outcomes
• Serious adverse events – any untoward medical occurrence
that at any dose resulted in death, was life-threatening,
required inpatient hospitalisation or prolongation of existing
hospitalisation, resulted in persistent or significant disability/
incapacity or was a congenital anomaly/birth defect (ICH 1994).
• Participant satisfaction with treatment.
• Participant withdrawal.
Search methods for identification of studies
We attempted to identify as many trials as possible that met the
inclusion criteria with our search strategy, without limitation by
language, publication type, status or date.
Electronic searches
We searched the following databases without language
restrictions.
• Cochrane Central Register of Controlled Trials (CENTRAL) 2018,
Issue 1 in the Cochrane Library (Appendix 1);
• MEDLINE (Ovid) 1966 to 25 January 2018 (Appendix 2);
• Embase.com 1970 to 25 January 2018 (Appendix 3);
• CINAHL (EBSCO) 1982 to 25 January 2018 (Appendix 4);
• Science Citation Index (ISI Web of Science) 1899 to 25 January
2018 (Appendix 5);
• Latin America and Caribbean Health Sciences (LILACS) 1982 to
25 January 2018 (Appendix 6).
Medical subject headings (MeSH) or equivalent and text word terms
were used. Where appropriate, MeSH terms and other subject
headings were exploded. We applied a modified version of the
Cochrane filter for the identification of RCTs, as published in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011). Searches were tailored to individual databases.
Searching other resources
We searched ClinicalTrials.gov (www.clinicaltrials.gov) and the
World Health Organization International Clinical Trials Registry
Platform (ICTRP) (apps.who.int/trialsearch/) for ongoing trials.
In addition, we checked the bibliographic references and cited
sources of any relevant identified studies to find additional
trials not identified by the electronic searches. To identify any
unpublished or grey literature, we searched the Internet, using
the Google Scholar search engine (www.googlescholar.com), with
selected terms from the above strategy. If only the abstract was
published, we attempted to contact the authors for further details,
or source the unpublished paper. One of the review authors (KR),
who is an Information Specialist, conducted the searches. All
searches are current as of 25 January 2018.
Data collection and analysis
Selection of studies
Four review authors (JH, PG, PVB, JD) independently assessed
the titles and abstracts of all studies identified by the search for
potential inclusion. Each of these authors independently selected
all potentially relevant studies for inclusion by applying the
selection criteria outlined in the 'Criteria for considering studies for
this review' section. We then compared these lists, discussed any
diHerences and either included or excluded the papers based on
a majority decision. A PRISMA study flow diagram is included in
Figure 1 (Moher 2009), which documents the screening process as
recommended in Part 2, Section 11.2.1 of the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011).
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Figure 1.   PRISMA study flow diagram.
 
 
Systemic corticosteroids for the management of cancer-related breathlessness (dyspnoea) in adults (Review)









Cochrane Database of Systematic Reviews
Figure 1.   (Continued)
 
Data extraction and management
Three review authors (AH, SK, JD) independently extracted data
using a standard form, and checked for agreement before entry into
Review Manager 5 (Review Manager 2014). The authors extracted
data that included information about the year of the study, study
design, number of participants treated, participant demographic
details, type of cancer, drug and dosing regimen, study design
(placebo or active control) and methods, study duration and follow-
up, outcome measures (measurement of dyspnoea and other
relevant outcomes), withdrawals and adverse events. We resolved
potential disagreements by discussion.
Assessment of risk of bias in included studies
Five review authors (AH, SK, JH, PG, JD) independently assessed
the risk of bias of each included study using the 'Risk of
bias' assessment method outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We resolved
potential disagreements by discussion. For each study, we assessed
the risk of bias for the following domains.
• Random sequence generation (checking for selection bias). We
assessed the method used to generate the allocation sequence
as: low risk of bias (any truly random process, e.g. random
number table; computer random number generator); or unclear
risk of bias (method used to generate sequence not clearly
stated). We excluded studies using a non-random process (e.g.
odd or even date of birth; hospital or clinic record number).
• Allocation concealment (checking for selection bias). The
method used to conceal allocation to interventions prior to
assignment determines whether intervention allocation could
have been foreseen in advance of, or during, recruitment, or
changed aMer assignment. We assessed the methods as: low risk
of bias (e.g. telephone or central randomisation; consecutively
numbered sealed opaque envelopes); unclear risk of bias
(method not clearly stated). We excluded studies that did not
conceal allocation (e.g. open list).
• Blinding of participants and personnel (checking for
performance bias). We assessed the methods used to blind
study participants and personnel from knowledge of which
intervention a participant received. We assessed methods
as: low risk of bias (study stated that it was blinded and
described the method used to achieve blinding, such as
identical tablets matched in appearance or smell, or a double-
dummy technique); unclear risk of bias (study stated that it was
blinded but did not provide an adequate description of how
it was achieved). Studies that were not double-blinded were
considered to have high risk of bias.
• Blinding of outcome assessment (checking for detection bias).
We assessed the methods used to blind study participants and
outcome assessors from knowledge of which intervention a
participant received. We assessed the methods as: low risk of
bias (study had a clear statement that outcome assessors were
unaware of treatment allocation, and ideally described how this
was achieved); unclear risk of bias (study stated that outcome
assessors were blind to treatment allocation but lacked a clear
statement on how it was achieved). Studies where outcome
assessment was not blinded were considered as having a high
risk of bias.
• Incomplete outcome data (checking for attrition bias due to
the amount, nature and handling of incomplete outcome data).
We assessed the methods used to deal with incomplete data
as: low risk (less than 10% of participants did not complete
the study or investigators used 'baseline observation carried
forward' analysis, or both); unclear risk of bias (investigators
used 'last observation carried forward' analysis); or high risk of
bias (investigators used 'completer' analysis).
• Selective reporting (checking for reporting bias). We assessed
whether primary and secondary outcome measures were
prespecified, and whether they were consistent with those
reported. We assessed the methods as: low risk of bias (study
protocol was available and all of the study's prespecified
primary and secondary outcomes that were of interest were
reported in the prespecified way, or if the study protocol
was not available but it was clear that the published reports
included all expected outcomes, including those that were
prespecified); high risk of reporting bias (not all of the study's
prespecified primary outcomes were reported; one or more
primary outcomes were reported using measurements, analysis
methods or subsets of the data (e.g. subscales) that were not
prespecified; one or more reported primary outcomes were not
prespecified (unless clear justification for their reporting was
provided, such as an unexpected adverse eHect); one or more
outcomes of interest in the review were reported incompletely
so that they could not be entered into a meta-analysis; the study
report did not include results for a key outcome that would be
expected to have been reported for such a study.
• Size of study (checking for bias confounded by small size).
We assessed studies as being at low risk of bias (200 or more
participants per treatment arm); unclear risk of bias (50 to 199
participants per treatment arm); or high risk of bias (fewer than
50 participants per treatment arm).
Measures of treatment e<ect
For dichotomous outcomes between groups, we estimated and
compared the risk ratio (RR) and 95% confidence intervals (CIs). For
continuous outcomes, we measured arithmetic mean and standard
deviation (SD) and reported the mean diHerence (MD) between
groups, with 95% CI. When an outcome was derived with diHerent
instruments measuring the same construct, we used the SMD with
95% CIs.
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Unit of analysis issues
We only included studies that randomised individual participants.
For trials containing multiple arms, we only included pair-wise
comparisons of each intervention arm to the control arm.
Dealing with missing data
We ascertained how the investigators analysed the data from
withdrawals, where possible. It was not possible to assess the
impact of missing data in sensitivity analyses due to the low study
numbers. In all cases, we aimed to perform intention-to-treat (ITT)
analyses.
Assessment of heterogeneity
There may be an eHect of diHerences between participants,
environment (inpatient versus outpatient) and outcome measures.
We assessed heterogeneity by using the I2 statistic. We considered
I2 values above 50% to represent substantial heterogeneity, in line
with Higgins 2011, and attempted to assess potential sources of
heterogeneity through subgroup analyses.
Assessment of reporting biases
We had planned to interpret the results in light of a visual inspection
of a funnel plot, but were unable to do so due to the lack of studies.
Data synthesis
We entered the data extracted from the included studies into
Review Manager 5, which we used for data synthesis (Review
Manager 2014). We had planned to pool data for each continuous
outcome and calculate the MD as an estimate of eHect size, using a
random-eHects model with 95% CIs, but were unable to do so due
to the lack of studies.
Quality of the evidence
Two review authors (AH, SK) planned to independently rate the
quality of evidence for dyspnoea relief using the three 'Domains
of Dyspnoea Measurement' of dyspnoea, serious adverse events,
participant satisfaction with treatment, and participant withdrawal
from trial. We used the GRADE system to assess the quality of
the available evidence using the GRADEpro Guideline Development
Tool soMware (GRADEpro GDT 2015), and the guidelines provided
in Chapter 12.2 of the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011). We presented the findings in a
'Summary of findings' table.
The GRADE approach employs five considerations (study
limitations, consistency of eHect, imprecision, indirectness and
publication bias) to assess the quality of the body of evidence for
each outcome. The GRADE system defines the quality of a body of
evidence as the extent to which one can be confident of an estimate
of eHect, namely:
• high: we are very confident that the true eHect lies close to that
of the estimate of the eHect;
• moderate: we are moderately confident that the true eHect lies
close to that of the estimate of the eHect;
• low: our confidence in the eHect estimate is limited: the true
eHect may be substantially diHerent from the estimate of the
eHect;
• very low: we have very little confidence in the eHect estimate:
the true eHect is likely to be substantially diHerent from the
estimate of eHect.
The GRADE system uses the following criteria for assigning a quality
level to a body of evidence (Chapter 12, Higgins 2011).
• High: randomised trials or double-upgraded observational
studies.
• Moderate: downgraded randomised trials or upgraded
observational studies.
• Low: double-downgraded randomised trials or observational
studies.
• Very low: triple-downgraded randomised trials, downgraded
observational studies or case series/case reports.
Factors that may decrease the quality level of a body of evidence
are:
• limitations in the design and implementation of available
studies suggesting high likelihood of bias;
• indirectness of evidence (indirect population, intervention,
control, outcomes);
• unexplained heterogeneity or inconsistency of results (including
problems with subgroup analyses);
• imprecision of results (wide CIs);
• high probability of publication bias.
Factors that may increase the quality level of a body of evidence are:
• large magnitude of eHect;
• all plausible confounding would reduce a demonstrated eHect
or suggest a spurious eHect when results show no eHect;
• dose–response gradient.
We decreased the grade rating by one (–1) or two (–2) (up to a
maximum of –3 to 'very low') for:
• serious (–1) or very serious (–2) limitation to study quality;
• important inconsistency (–1);
• some (–1) or major (–2) uncertainty about directness;
• imprecise or sparse data (–1); or
• high probability of reporting bias (–1).
'Summary of findings' table
We included a ‘Summary of findings’ table to present the main
findings in a transparent and simple tabular format. In particular,
we included key information concerning the quality of evidence,
the magnitude of eHect of the interventions examined, and the
sum of available data on dyspnoea relief, as measured by the
three domains of dyspnoea, i.e. intensity of dyspnoea (sensory-
perceptual experience, as measured by ratings of breathlessness
intensity), quality of dyspnoea (aHective distress, as measured
by ratings of severity of distress), and burden of breathlessness/
impact on function (as measured by ratings of functional ability,
quality of life or health status), adverse events, patient satisfaction
with treatment, and participant withdrawal from trial.
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Subgroup analysis and investigation of heterogeneity
There were insuHicient data available to perform subgroup
analyses based on type of systemic corticosteroid, dose, type of
cancer and length of the trial.
Sensitivity analysis
We had planned to examine the robustness of the meta-analyses by
conducting sensitivity analyses using diHerent components of the
'Risk of bias' assessment – particularly those relating to selection
bias, and trial size, to see if any of these factors influenced the
results. We had also planned to investigate variation across studies
(heterogeneity) by comparing a random-eHects model with a fixed-
eHect model. We were unable to perform any sensitivity analyses
due to the low number of studies included in the meta-analysis, and
the small number of participants in each comparison.
R E S U L T S
Description of studies
See: Characteristics of included studies and Characteristics of
excluded studies tables.
Results of the search
The PRISMA diagram outlines the number of records identified in
the search and screening process for these papers (Figure 1). In
the initial database search, we identified 1350 records. None were
identified through other sources. Of these, 285 were duplicates
and we rejected 1047 based on information given in the title and
abstract. We identified 18 publications for full-text retrieval, and
excluded 16 of these records during screening. The reasons for
exclusion of each study are described in the Characteristics of
excluded studies table. Two placebo-controlled studies met the
inclusion criteria for this review (Hui 2016; Yennurajalingam 2013).
We evaluated the results relative to dyspnoea intensity/dyspnoea
relief at one week from baseline (day seven and eight), since this
was the only time that could be standardised across both trials.
Included studies
We identified two studies meeting the inclusion criteria (Hui
2016; Yennurajalingam 2013). These two studies enrolled 157
participants (37 and 120 participants per study), of whom 114
were included in the analyses. The studies compared oral
dexamethasone to placebo. One study lasted seven days, and the
duration of the other study was 15 days. A detailed description of
the included studies can be found in the Characteristics of included
studies table.
Primary disease sites
We have shown the primary disease sites in Table 1. Eligibility
criteria in the included trials did not specify a particular cancer.
Types of studies
We included studies in which corticosteroids were used for cancer-
related dyspnoea, or any other indication. The studies assessed
dyspnoea relief intensity, quality and burden/impact on function.
Dyspnoea as a primary endpoint
Of the two included studies, one measured change in dyspnoea
intensity as a primary endpoint (Hui 2016). The other study
measured fatigue (a change in the Functional Assessment of
Chronic Illness Therapy – Fatigue (FACIT-F) subscale) as the primary
outcome (Yennurajalingam 2013).
Types of corticosteroids studied
Both studies used oral dexamethasone. One study compared
dexamethasone (8 mg twice a day for four days, then 4 mg twice a
day for three days) to placebo (Hui 2016). The other study compared
dexamethasone (8 mg/day) to placebo (Yennurajalingam 2013).
Dyspnoea measurement tools
The studies used diHerent measurement tools to measure
dyspnoea relief intensity, quality, burden/impact on function and
quality of life.
• Dyspnea Numeric Rating Scale 'now' (NRS) 0 to 10 (0 = no
shortness of breath) (Hui 2016).
• Edmonton Symptom Assessment Scale (ESAS) 0 to 10 (0 = no
shortness of breath) – dyspnoea mean past 24 hours; fatigue,
drowsiness and appetite (Hui 2016; Yennurajalingam 2013).
• Modified Dyspnea Borg Scale (0 to 10) (0 = no shortness of breath
at all) (Hui 2016).
• Cancer Dyspnea Scale 1 to 5 (higher score indicates a greater
intensity of dyspnoea) (Hui 2016).
• European Organization for Research and Treatment of Cancer
(EORTC) Quality of Life Questionnaire-Core 30 – dyspnoea past
week (Hui 2016).
• Global Symptom Evaluation (Hui 2016).
Excluded studies
We excluded 16 studies and provided reasons for exclusion in the
Characteristics of excluded studies table.
Risk of bias in included studies
We assessed each study using the Cochrane 'Risk of bias' tool. We
presented overall findings in the 'Risk of bias' graph (Figure 2),
which presents the authors' judgements about each risk of bias
domain as percentages across all included studies. We have shown
the authors' judgements about each risk of bias domain for each
included study in the 'Risk of bias' summary (Figure 3).
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Figure 2.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
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Both included studies reported that they were randomised. Only
one study described the method used to generate their random
sequence (Hui 2016), thus we judged the second study to have an
unclear risk of bias (Yennurajalingam 2013).
Allocation concealment
For allocation concealment, only one study used pharmacy
randomisation and was at low risk in this regard (Hui
2016). The other study was at unclear risk, as there was
insuHicient information on the method of allocation concealment
(Yennurajalingam 2013).
Blinding
Both studies were at low risk, with blinding of participants,
personnel and outcome assessments reported (Hui 2016;
Yennurajalingam 2013).
Incomplete outcome data
The two studies were at high risk for attrition bias, as greater
than 10% of participants could not be evaluated, thereby
leaving a gap in the evidence (i.e. 6/19 participants receiving
the intervention and 3/18 participants receiving placebo (Hui
2016); 19/62 participants receiving the intervention, and 17/58
participants receiving placebo (Yennurajalingam 2013)).
Selective reporting
Neither study identified reporting gaps. Therefore, we judged these
studies at low risk for reporting bias.
Other potential sources of bias
Small studies are thought to be at increased risk of bias as they are
unlikely to be adequately powered. Neither study was large enough
to be at low risk of bias (more than 200 participants per arm). We
judged one study to have an unclear risk of bias due to sample
size (50 to 199 participants per arm) (Yennurajalingam 2013). The
other study was at high risk of bias because of their small number
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of participants (fewer than 50 participants per treatment arm) (Hui
2016).
E<ects of interventions
See: Summary of findings for the main comparison Systemic
corticosteroids compared with placebo for the management of
cancer-related breathlessness (dyspnoea)
Primary outcome
Participant-reported dyspnoea intensity, quality and burden
For the meta-analysis, both studies provided change in dyspnoea
intensity score (on a scale of 0 to 10; lower score = less
breathlessness) and the standard deviation at one week (Hui 2016;
Yennurajalingam 2013). The studies included 157 participants at
baseline and 114 participants aMer one week of corticosteroid
treatment (dexamethasone). AMer one week, the dexamethasone
group reported less dyspnoea intensity than the control group (MD
–0.85, 95% CI –1.73 to 0.03; P = 0.06; Analysis 1.1), although we
were uncertain as to whether corticosteroids truly had an important
eHect on dyspnoea as results were imprecise.
Both studies used a numeric rating scale to assess the intensity of
dyspnoea 'now' – an 11-point dyspnoea numeric rating scale (0 to
10).
We judged the quality of the evidence for the primary outcome
of dyspnoea relief (intensity) to be very low (see Summary of
findings for the main comparison). We downgraded the quality
of the evidence once for imprecision due to the small number of
participants in the included studies, and twice for very serious study
limitations (likely selection and attrition bias).
One study measured aHective distress/quality of dyspnoea (Hui
2016), using the Cancer Dyspnea Scale eHort, discomfort and
anxiety variables (Domain 2 of Parshall's 'Domains of Dyspnoea
Measurement') and results were similar between groups. We
judged the quality of the evidence for the primary outcome of
dyspnoea relief (quality) to be very low. We downgraded the quality
of the evidence three times for imprecision due to the small number
of participants in the included study, inconsistency, and serious
study limitations (likely attrition bias).
Both studies assessed impact of dyspnoea on function/quality of
life. Hui 2016 assessed dyspnoea quality and burden/impact on
function and quality of life using the European Organization for
Research and Treatment of Cancer Quality of Life Questionnaire-
Core 36 (EORTC QLQ-C30) dyspnoea 'past week,' which favoured
dexamethasone compared to placebo at day four, but not at
day seven. However, it was unclear whether dexamethasone had
a significant eHect on dyspnoea as results were imprecise. In
Yennurajalingam 2013, FACIT physical well-being scores showed
significantly better improvement at days eight (P = 0.007) and 15
(P = 0.002) in the dexamethasone group compared with the control
group, however there were no significant changes for FACIT social/
family, emotional or functional scales. We judged the quality of
the evidence for the primary outcome of dyspnoea relief (burden)
to be very low. We downgraded the quality of the evidence three
times for imprecision due to the small number of participants in
the included studies, inconsistency, and serious study limitations
(likely selection and attrition bias).
Secondary outcomes
Serious adverse events
The severity of adverse events was not properly defined, making
it diHicult to assess this outcome. Hence we evaluated reported
‘adverse events’. In both studies, the frequency of adverse events
was similar between groups, and dexamethasone was generally
well tolerated. We judged the quality of the evidence for this
outcome to be very low. We downgraded the quality of the evidence
three times due to serious study limitations (likely selection and
attrition bias), inconsistency, and imprecision due to the small
number of participants in the included studies.
Participant satisfaction with treatment
Neither study measured participant satisfaction with treatment.
Participant withdrawal
There were 6/41 (15%) participant withdrawals in Hui 2016, and
48/132 (36%) in Yennurajalingam 2013. We judged the quality of
the evidence for this outcome to be very low. We downgraded
the quality of the evidence three times from high to very low
due to serious study limitations (likely selection and attrition
bias), inconsistency, and imprecision due to the small number of
participants in the included studies.
D I S C U S S I O N
Summary of main results
The objective of this systematic review was to assess the eHects
of corticosteroids on dyspnoea in adults with cancer-related
dyspnoea. Two studies with 157 participants met the inclusion
criteria, of whom 114 were evaluable. The included studies
assessed dexamethasone (4 mg/day or up to 16 mg/day) compared
to placebo.
Both studies were evaluated for relief of dyspnoea in the meta-
analysis (Hui 2016; Yennurajalingam 2013). We reported data aMer
one week of intervention, since this was the only time that could be
standardised across both trials. The following conclusion regarding
the eHectiveness of corticosteroids for relief of dyspnoea should
be interpreted with consideration of the small number of eligible
studies with small numbers of participants in each treatment arm,
and diHerence in dexamethasone dose. The quality of evidence was
very low due to very serious study limitations and imprecision.
• There was no clear diHerence in favour of dexamethasone over
placebo (MD –0.85, 95% –1.73 to 0.03) for dyspnoea at one week
of intervention (P = 0.06).
• There were insuHicient data to evaluate diHerent subgroups,
such as drug type, route of administration, dosage and diHerent
primary disease types.
Overall completeness and applicability of evidence
We identified two studies that met the inclusion criteria and
included these studies in the meta-analysis for dyspnoea relief/
change in dyspnoea intensity from baseline. There was a lack
of studies for planned comparisons, and insuHicient data for
subgroup analyses. The results were also influenced by diHerences
in dosages, comparators and heterogeneity of study populations.
The studies excluded people with overlying conditions that would
be expected to respond to corticosteroids (e.g. COPD and superior
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vena cava obstruction). Comparators included in the meta-analysis
included dexamethasone compared to placebo. We also included
trials where dyspnoea was not the primary outcome.
Quality of the evidence
The quality of evidence for breathlessness intensity was very
low, downgraded once for imprecision due to the small number
of participants in the included studies, and twice for very
serious study limitations (likely selection and attrition bias). Both
studies measured participant-reported dyspnoea relief/intensity
of dyspnoea at similar time points, and burden of dyspnoea/
impact on function and quality of life (Hui 2016; Yennurajalingam
2013). Only one study measured aHective distress/quality of
dyspnoea (Hui 2016). We judged the quality of the evidence for
the outcomes breathlessness quality and burden to be very low,
downgraded three times for imprecision due to the small number
of participants in the included studies, inconsistency, and serious
study limitations.
We judged the quality of the evidence for the outcomes adverse
events and withdrawals to be very low, downgraded three
times due to serious study (likely selection and attrition bias),
inconsistency, and imprecision due to the small number of
participants in the included studies. Neither study measured
participant satisfaction with treatment.
Other concerns regarding quality of the evidence included the
fact that one study was an inadequately powered pilot study with
greater than 10% dropouts in both arms prior to day seven (Hui
2016). The other study had a very high participant withdrawal from
trial, with approximately 30% dropouts by day 15 (Yennurajalingam
2013). Therefore, the current body of evidence does not allow
a robust conclusion. We have very little confidence in the eHect
estimate, and the true eHect is likely to be substantially diHerent
from the estimate of eHect.
Potential biases in the review process
To minimise bias, three review authors independently extracted
data and five authors assessed risk of bias. Due to the lack of studies
we were unable to determine if there was evidence of small-study
eHects.
Agreements and disagreements with other studies or
reviews
We found no other studies or reviews that assessed the quality
of evidence and eHects of systemic corticosteroid use for the
management of cancer-related dyspnoea in adults.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
For people with dyspnoea
There is insuHicient evidence to support or refute the suggestion
that systemic corticosteroids have any eHicacy in cancer-related
breathlessness (dyspnoea) in adults.
For clinicians
There is insuHicient evidence to support or refute the suggestion
that systemic corticosteroids have any eHicacy in cancer-related
breathlessness (dyspnoea) in adults. This may be particularly
relevant when considering the potential toxicity of corticosteroids,
especially following prolonged use.
For policy makers
There is insuHicient evidence to support or refute the suggestion
that systemic corticosteroids have any eHicacy in cancer-related
breathlessness (dyspnoea) in adults.
For funders
There is insuHicient evidence to support or refute the suggestion
that systemic corticosteroids have any eHicacy in cancer-related
breathlessness (dyspnoea) in adults (that is not related to a number
of specific respiratory or inflammatory (or both) conditions).
Implications for research
General implications
This review has highlighted a marked paucity of research in the
subject area. Future robust, double-blind randomised trials with
significant numbers of participants (e.g. over 200 per treatment
arm) are needed to evaluate the safety and eHectiveness of
systemic corticosteroids in the management of cancer-related
dyspnoea in adults.
Design
There are few randomised controlled trials assessing the benefit
of systemic corticosteroids in cancer-related dyspnoea. There is
a need for further research to observe the eHects of systemic
corticosteroids on all three domains of dyspnoea measurement
(i.e. dyspnoea intensity, dyspnoea quality and dyspnoea burden/
impact on function) alongside participant satisfaction with
treatment, and assessment of serious adverse events. Further trials
with increased number of participants are needed to evaluate the
eHectiveness of corticosteroids for the management of dyspnoea
in adults with cancer-related breathlessness. Comparators should
include placebo versus combinations of dexamethasone with
other antidyspnoea agents, since the mechanism of cancer-related
dyspnoea is not well understood and involves multiple sites of
action in the body.
Measurement (endpoints)
There is currently no standard outcome measure for the
measurement of cancer-related dyspnoea. This must be
determined prior to future studies. Appropriate time points for
measuring the eHect of corticosteroids on breathlessness also need
to be determined.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 




Study duration: randomised trial for 7 days with an open-label extension phase for another 7 days
Participants 37 adults (19 intervention, 18 control) with a diagnosis of cancer with clinical or radiological evidence
of lung involvement.
Exclusion criteria: people with delirium, oxygen saturation < 90% despite supplemental oxygen > 6
L/minute, diabetes mellitus uncontrolled on oral hypoglycaemic agents or insulin, severe anaemia,
open wound that had not healed, infection requiring antibiotics or major surgery within the past 2
weeks, chronic obstructive pulmonary disease exacerbation and heart failure exacerbation, receiving
active or recent chronic systemic corticosteroids (> 14 days), or using megestrol acetate, or receiving
chemotherapy or expected to start within 1 week of study enrolment.
Interventions Participants randomised into 2 groups.
Intervention: dexamethasone 8 mg (2 × 4 mg capsules) orally twice a day for 4 days, then 4 mg given
orally twice a day for 3 days
Control: identical-appearing placebo capsules
After 1 week, all participants received dexamethasone 4 mg orally twice a day for 7 days in an open-la-
bel extension.
Outcomes Primary outcome: proportion of participants who completed the blinded phase of the study (35/37 par-
ticipants). Dyspnoea assessed at baseline, days 4 (SD 2) and days 7 (SD 2) using the ESAS, Modified Dys-
pnea Borg Scale, Cancer Dyspnea Scale and 1 item on dyspnoea from the EORTC Quality of Life Ques-
tionnaire.
Secondary outcomes: fatigue, drowsiness and appetite using ESAS.
Notes Dexamethasone was associated with rapid improvement in dyspnoea and was well tolerated; however,
sample size was small and the study was not powered for between-arm comparisons.
Funding: MD Anderson Cancer Center Institutional Research Grant. Authors also supported in part from
American Cancer Society Mentored Research Scholar Grant in Applied and Clinical Research and Na-
tional Institutes of Health Grants.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation performed using permuted blocks.
Allocation concealment
(selection bias)





Low risk Placebo capsules were identical in appearance.
Hui 2016 
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All outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "Both participants and research staH conducting the study assess-





High risk Used 'completer' analysis. 2 participants did not complete the 7-day interven-
tion and 4 participants did not complete from the placebo group.
Selective reporting (re-
porting bias)
Low risk None detected




Methods Randomised, double-blind, placebo-controlled trial
Outpatients at 3 study centres
Country: USA
Year: not described
Study duration: 14 days
Participants 120 (62 intervention, 58 control) people with advanced cancer with ≥ 3 symptoms during the previous
24 hours (e.g. fatigue, pain, nausea, loss of appetite, depression, anxiety or sleep disturbance) with
mean intensity of ≥ 4/10 on the ESAS.
Interventions Participants randomised into 2 groups
Intervention: dexamethasone 4 mg orally twice per day for 14 days.
Control: placebo orally twice per day for 14 days.
Outcomes Primary outcome: fatigue, measured by a change in the FACIT-F subscale from baseline to day 15.
Secondary outcomes: anorexia, anxiety, depression, shortness of breath and symptom distress scores.
Used the FACIT-F, ESAS, Hospital Anxiety and Depression Scale, and Functional Assessment of Cancer
Therapy-Anorexia-Cachexia instruments.
Notes Dexamethasone was more effective than placebo in improving cancer-related fatigue and quality of
life. There was a non-significant improvement in shortness of breath at days 8 and 15.
Funding: American Cancer Society Mentored Research Scholar Grant.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation method not specified.
Allocation concealment
(selection bias)
Unclear risk Method of concealment not described.
Yennurajalingam 2013 
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk All members of the research team except the investigational pharmacist and




High risk 19/62 participants receiving dexamethasone were not evaluable. 17/58 partici-
pants receiving placebo were not evaluable.
Selective reporting (re-
porting bias)
Low risk None detected
Other bias Unclear risk Sample size: 120 participants; 50–199 participants per treatment arm.
Yennurajalingam 2013  (Continued)
EORTC: European Organization for Research and Treatment of Cancer; ESAS: Edmonton Symptom Assessment System; FACIT-F: Functional
Assessment of Chronic Illness – Fatigue; SD: standard deviation; VAS: visual analogue scale.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Davidson 2010 Not an RCT. Literature review on management of refractory dyspnoea.
Delgado 1986 Did not study breathlessness.
Elsayem 2007 Case studies only.
Jantarakupt 2005 Not an RCT. Literature review on dyspnoea management in lung cancer.
Lui 2013 Not a double-blind study.
McCannon 2012 Not an RCT. Literature review about dyspnoea management in lung cancer.
North 2003 Wrong intervention. Used intrapleural administration of methylprednisolone acetate for malignant
pleural effusion.
Ripamonti 1999 Not an RCT. Literature review of dyspnoea in advanced cancer.
Simoff 2013 Not an RCT. Literature review of symptom management in people with lung cancer.
Simon 2012 Systematic review of refractory dyspnoea, but found no studies of corticosteroids.
Skřičková 2013 Not an RCT. Literature review about management of respiratory symptoms in people with ad-
vanced lung cancer.
Thomas 2002 Not an RCT. Literature review on management of dyspnoea.
Viola 2008 Systematic review of management of dyspnoea in people with cancer. Found no studies of sys-
temic corticosteroids.
White 1984 Not an RCT. All participants received corticosteroids for bleomycin-induced pneumonitis.
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Study Reason for exclusion
Yennu 2015 Abstract only. Studied symptom clusters, and not breathlessness as an individual outcome.
Yennurajalingam 2016 Studied symptom clusters, and not breathlessness as an individual outcome.
RCT: randomised controlled trial.
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Breathlessness (dyspnoea) at one week




Statistical method Effect size
1 Breathlessness (dyspnoea) 2 114 Mean Difference (IV, Random, 95% CI) -0.85 [-1.73, 0.03]
 
 
Analysis 1.1.   Comparison 1 Breathlessness (dyspnoea) at one week, Outcome 1 Breathlessness (dyspnoea).
Study or subgroup Dexamethasone Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Hui 2016 16 -1.8 (2.8) 14 -1.3 (1.9) 26.74% -0.5[-2.2,1.2]
Yennurajalingam 2013 43 -1.6 (2.4) 41 -0.6 (2.4) 73.26% -0.98[-2.01,0.05]
   
Total *** 59   55   100% -0.85[-1.73,0.03]
Heterogeneity: Tau2=0; Chi2=0.22, df=1(P=0.64); I2=0%  
Test for overall effect: Z=1.9(P=0.06)  
Favours dexamethasone 105-10 -5 0 Favours placebo
 
 
A D D I T I O N A L   T A B L E S
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Study Breast Head, neck and lung Gastrointestinal Gynaecological Genitourinary Sarcoma Not specified
Hui 2016 — 37 — — — — 4
Yennurajalingam 2013 13 45 39 9 10 9 7
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Adrenal Cortex Hormones] explode all trees
#2 MeSH descriptor: [Betamethasone] explode all trees
#3 MeSH descriptor: [Fludrocortisone] explode all trees
#4 MeSH descriptor: [Dexamethasone] explode all trees
#5 MeSH descriptor: [Methylprednisolone] explode all trees
#6 MeSH descriptor: [Prednisolone] explode all trees
#7 MeSH descriptor: [Triamcinolone] explode all trees
#8 MeSH descriptor: [Beclomethasone] explode all trees
#9 (corticoid* or corticosteroid* or glucocorticoid* or betamethasone or fludrocortisone or cortisone or deflazacort or dexamethasone or
hydrocortisone or methylprednisolone or prednisolone or triamcinolone or beclomethasone)
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9
#11 MeSH descriptor: [Dyspnea] explode all trees
#12 (dysp* or breathless* or ((short or labor* or diHicult*) near/3 breath*)):ti,ab
#13 #11 or #12
#14 MeSH descriptor: [Neoplasms] explode all trees
#15 (cancer* or carcinoma* or malignan* or adenocarcinoma* or mesothelioma* or tumour* or tumor*)
#16 #14 or #15
#17 #10 and #13 and #16
Appendix 2. MEDLINE via Ovid search strategy
1. exp Adrenal Cortex Hormones/
2. (corticoid* or corticosteroid* or glucocorticoid*).tw.
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34. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26








42. 35 or 36 or 37 or 38 or 39 or 40 or 41
43. exp Dyspnea/
44. "dyspn*".tw.
45. (short* adj2 breath*).tw.
46. (breath* adj2 diHicult*).tw.
47. (labo*r* adj2 breath*).tw.
48. "breathless*".tw.
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49. 43 or 44 or 45 or 46 or 47 or 48
50. randomized controlled trial.pt.








59. 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58
60. exp animals/ not humans.sh.
61. 59 not 60
62. 34 and 42 and 49 and 61
Appendix 3. Embase search strategy
(('corticosteroid'/exp OR ('betamethasone'/exp OR betamethasone:ti,ab) OR ('cortisone'/exp OR cortisone:ti,ab) OR ('deflazacort'/
exp OR deflazacort:ti,ab) OR ('fludrocortisone'/exp OR fludrocortisone:ti,ab) OR ('dexamethasone'/exp OR dexamethasone:ti,ab) OR
('hydrocortisone'/exp OR hydrocortisone:ti,ab) OR ('methylprednisolone'/exp OR methylprednisolone:ti,ab) OR ('prednisolone'/exp OR
prednisolone:ti,ab) OR ('triamcinolone'/exp OR triamcinolone:ti,ab)) OR beclometasone:ti,ab OR beclomethasone:ti,ab)
AND
(('neoplasm'/exp OR tumor*:ti,ab OR tumour*:ti,ab OR cancer*:ti,ab OR carcinoma*:ti,ab OR adenocarcinoma*:ti,ab OR malignan*:ti,ab)
OR mesothelioma)
AND
(random*:ab,ti OR placebo*:de,ab,ti OR (double NEXT/1 blind*):ab,ti)
AND
('cheyne stokes breathing'/exp OR dyspn*:ti,ab OR breathless*:ti,ab OR (short* NEAR/2 breath*):ti,ab OR 'dyspnea'/exp/mj)
Appendix 4. CINAHL search strategy
S47 S34 NOT S46
S46 S34 AND S45
S45 S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42 OR S43 OR S44
S44 (MH "Quantitative Studies")
S43 (MH "Placebos")
S42 TX placebo
S41 TX random* W1 allocat*
S40 (MH "Random Assignment")
S39 TX random* control* trial*
S38 TX (trebl* OR tripl* OR doubl* OR singl*) N1 (blind* OR mask*)
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S37 TX clinic* N1 trial*
S36 PT Clinical Trial
S35 (MH "Clinical Trials+")
S34 S32 AND S33
S33 S20 AND S23
S32 S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR S31
S31 TX breathless*
S30 TX labo#r* N2 breath*
S29 labo#r* N2 breath*
S28 TX breath N2 diHicult*
S27 TX short* n2 breath*
S26 TX cheyne stokes
S25 TX dyspn*
S24 (MH "Dyspnea+")
S23 S21 OR S22
S22 TX malignan* OR tumor* OR tumour* OR cancer* OR carcinoma* OR adenocarcinoma* OR mesothelioma*
S21 (MH "Neoplasms+")

















S3 TX adrenal N2 hormon*
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S2 TX corticoid* OR corticosteroid* OR glucocorticoid*
S1 (MH "Adrenal Cortex Hormones+")
Appendix 5. Science Citation Index (ISI Web of Science) search strategy
TOPIC: (corticoid* OR corticosteroid* OR glucocorticoid* OR betamethasone OR Fludrocortisone OR cortisone OR dexamethasone OR
hydrocortisone OR methylprednisolone OR prednisolone OR triamcinolone OR beclomethasone) AND TOPIC: (cancer* OR carcinoma* OR
adenocarcinoma* OR malignan* OR tumour* OR tumor*) AND TOPIC: (dyspn* OR breath*)
Appendix 6. LILACS search strategy
1. w:((dyspnoea OR dyspnea) AND (cancer OR malignancy OR malignant OR tumours OR tumors OR carcinoma) AND (corticosteroids
OR glucocorticoids OR dexamethasone OR hydrocortisone OR methylprednisolone OR prednisolone OR betamethasone)) AND
(instance:"regional") AND ( type_of_study:("clinical_trials"))
tw:((mh:(adrenal cortex hormones)) OR (tw:(corticosteroid* OR corticoid* OR glucocorticoid* OR betamethasone OR fludrocortisone OR
cortisone OR dexamethasone OR hydrocortisone OR methylprednisolone OR prednisolone OR triamcinolone OR beclomethasone)) AND
(mh:(neoplasms)) OR (tw:(cancer* OR malignan* OR carcinoma* OR adenocarcinoma* OR tumour* OR tumor* OR mesothelioma)) AND
(mh:(respiratory physiological phenomena)) OR (tw:(dyspn* OR "cheyne stokes" OR breathless*))) AND (instance:"regional") AND ( db:
("LILACS") AND type_of_study:("cohort" OR "case_control" OR "clinical_trials"))
C O N T R I B U T I O N S   O F   A U T H O R S
 
DraM the protocol AH, JD
Develop and run the search strategy KR
PaPaS Information Specialist provided sup-
port
Obtain copies of studies KR
Select which studies to include JH, PG, PVB, JD
Extract data from studies AH, SK, JD
Enter data into Review Manager 5 AH
Assess risk of bias AH, SK, JH, PG, JD
Carry out the analysis AH, SK
Interpret the analysis JH, PG, AH, SK, JD
DraM the final review AH, KR, JD
Update the review AH, JH, PG, KR
 
D E C L A R A T I O N S   O F   I N T E R E S T
AH: none known.
JD: none known; JD is a trainee physician in palliative medicine and manages patients with dyspnoea due to advanced cancer.
PG: none known; PG is a specialist palliative medicine physician and manages patients with dyspnoea due to advanced cancer.
SK: none known.
KR: none known.
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PVB: none known; PVB is a specialist palliative medicine physician and manages patients with dyspnoea due to advanced cancer.
JH: none known; JH is a specialist palliative medicine physician and manages patients with dyspnoea due to advanced cancer. JH receives
royalties from Oxford University Press.
S O U R C E S   O F   S U P P O R T
Internal sources
• In kind and operational funds, Australia.
Mater Research – The University of Queensland, School of Pharmacy and Menzies Health Institute Queensland, GriHith University, The
Mater Palliative Care Research Fund and St Vincent's Hospital Brisbane.
External sources
• No sources of support supplied
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
We had planned for two authors to independently extract data and perform assessments. At review stage, three review authors (AH, SK,
JD) independently extracted data from the studies. Five review authors (AH, SK, JH, PG, JD) independently assessed the risk of bias of
each included study.
We stated our intention to search the metaRegister of controlled trials (mRCT) (www.controlled-trials.com/mrct), but this database is under
review and not available to search.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Administration, Oral;  Adrenal Cortex Hormones  [administration & dosage]  [adverse eHects]  [*therapeutic use];  Dexamethasone
 [administration & dosage]  [adverse eHects]  [*therapeutic use];  Dyspnea  [*drug therapy]  [etiology];  Neoplasms  [*complications]
MeSH check words
Adult; Humans
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